0000904454-20-000300.txt : 20200320 0000904454-20-000300.hdr.sgml : 20200320 20200320131614 ACCESSION NUMBER: 0000904454-20-000300 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200318 FILED AS OF DATE: 20200320 DATE AS OF CHANGE: 20200320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kapusta Matthew C CENTRAL INDEX KEY: 0001536290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 20731280 MAIL ADDRESS: STREET 1: 7358 MCVAY ROAD CITY: GERMANTOWN STATE: TN ZIP: 38138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-03-18 0001590560 uniQure N.V. QURE 0001536290 Kapusta Matthew C C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 11058BP NETHERLANDS 1 1 0 0 CEO, CFO, Managing Director Ordinary Shares 2020-03-18 4 M 0 5626 7.53 A 324168 D Ordinary Shares 2020-03-18 4 S 0 1888 40.57 D 322280 D Ordinary Shares 2020-03-18 4 S 0 2100 41.45 D 320180 D Ordinary Shares 2020-03-18 4 S 0 1438 42.40 D 318742 D Ordinary Shares 2020-03-18 4 S 0 200 43.70 D 318542 D Stock Option (Right to Buy) 7.53 2020-03-18 4 M 0 5626 0 A 2026-09-29 Ordinary Shares 5626 87035 D The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.02 to $40.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.03 to 42.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.06 to $43.02. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.48 to $43.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested 25% on September 29, 2017 (the first anniversary of the date of grant), and vests 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates. /s/ Christian Klemt, Attorney-in-Fact 2020-03-20